» Articles » PMID: 22533963

Type I Interferons Impair BDNF-induced Cell Signaling and Neurotrophic Activity in Differentiated Human SH-SY5Y Neuroblastoma Cells and Mouse Primary Cortical Neurons

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 2012 Apr 27
PMID 22533963
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Type I interferons (IFNs) have been shown to act on neurons and to cause neuronal damage through mechanisms not completely defined. Here, we investigated the effects of type I IFNs on brain-derived neurotrophic factor (BDNF)-induced TrkB receptor signaling and neurotrophic activity. In retinoic acid-treated human SH-SY5Y neuroblastoma cells and mouse primary cortical neurons, long-term exposure to IFNs curtailed BDNF-induced activation of phosphatidylinositol 3-kinase, phospholipase Cγ and extracellular-regulated kinases 1 and 2 signaling. Moreover, IFN-β inhibited BDNF-induced cell survival, neurite outgrowth, and expression of neuronal markers, such as neurofilament proteins, growth-associated protein-43 and glutamate α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunit GluR1. The IFN inhibitory effects were associated with down-regulation of TrkB and inhibition of TrkB autophosphorylation. In SH-SY5Y cells, blockade of either Janus kinase with pyridone 6 or signal transducer and activator of transcription (STAT) 1 with siRNA transfection attenuated IFN-β-induced TrkB down-regulation. Quantitative real time RT-PCR indicated that IFN-β significantly reduced TrkB mRNA levels. Moreover, blockade of protein kinase R counteracted IFN-β-induced inhibition of TrkB expression and signaling. These data indicate that in neuronal cells IFNs negatively regulate BDNF signaling and neurotrophic activity through inhibition of TrkB activation and Janus kinase/Signal transducer and activator of transcription-dependent down-regulation of TrkB.

Citing Articles

Exploring the mechanisms under Zuogui Pill's treatment of ischemic stroke through network pharmacology and experimental verification.

Li L, Liu Y, Zheng Y, Zhu J, Wu D, Yan X Front Pharmacol. 2023; 14:1153478.

PMID: 37426810 PMC: 10323140. DOI: 10.3389/fphar.2023.1153478.


Breaking down the cellular responses to type I interferon neurotoxicity in the brain.

Viengkhou B, Hofer M Front Immunol. 2023; 14:1110593.

PMID: 36817430 PMC: 9936317. DOI: 10.3389/fimmu.2023.1110593.


HERV-W ENV Induces Innate Immune Activation and Neuronal Apoptosis via linc01930/cGAS Axis in Recent-Onset Schizophrenia.

Li X, Wu X, Li W, Yan Q, Zhou P, Xia Y Int J Mol Sci. 2023; 24(3).

PMID: 36769337 PMC: 9917391. DOI: 10.3390/ijms24033000.


Porous Silicon Nanoparticles Targeted to the Extracellular Matrix for Therapeutic Protein Delivery in Traumatic Brain Injury.

Waggoner L, Kang J, Zuidema J, Vijayakumar S, Hurtado A, Sailor M Bioconjug Chem. 2022; 33(9):1685-1697.

PMID: 36017941 PMC: 9492643. DOI: 10.1021/acs.bioconjchem.2c00305.


Upregulation of p75NTR by Histone Deacetylase Inhibitors Sensitizes Human Neuroblastoma Cells to Targeted Immunotoxin-Induced Apoptosis.

Dedoni S, Olianas A, Manconi B, Collu M, Tuveri B, Vincis M Int J Mol Sci. 2022; 23(7).

PMID: 35409209 PMC: 8998832. DOI: 10.3390/ijms23073849.